Physician profile
Michael Gray
NPI 1457322877
$2,848.15
in general payments reported to CMS, 2019-2025
20 companies · $180 in 2025
The $180 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $238 · 2020: $296 · 2021: $434 · 2022: $423 · 2023: $286 · 2024: $991 · 2025: $180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $896 · Long Term Medical Supply Or Device Loan: $560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $896.39 |
| Long Term Medical Supply Or Device Loan | $560.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $811.01 | 2019-2025 | Clareon |
| Ocular Therapeutix, INC. | $664.04 | 2019-2024 | Dextenza |
| Mallinckrodt Hospital Products INC. | $340.07 | 2020-2025 | Acthar |
| Sun Pharmaceutical Industries INC. | $148.65 | 2019-2025 | Cequa |
| Oyster Point Pharma, INC. | $131.42 | 2022-2024 | Tyrvaya |
| Allergan, INC. | $120.21 | 2019-2021 | |
| Abbvie INC. | $118.21 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $104.43 | 2019-2023 | |
| Aerie Pharmaceuticals, INC. | $94.22 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $70.25 | 2020-2021 | |
| Tarsus Pharmaceuticals, INC. | $45.69 | 2024-2025 | Xdemvy |
| Horizon Therapeutics Plc | $31.54 | 2020-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $28.99 | 2021 | |
| Rayner Intraocular Lenses Limited | $27.96 | 2022-2023 | Omidria, Rayone Spheric, Rayone Emv |
| Johnson & Johnson Vision Care, INC. | $27.42 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $24.09 | 2022 | |
| Rxsight INC | $18.23 | 2024 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Injector Handpiece |
| Bausch & Lomb Americas INC. | $14.81 | 2023 | Vyzulta, Lotemax Sm, Zylet |
| Ani Pharmaceuticals, INC. | $13.64 | 2024 | Purified Cortrophin Gel |
| Eyevance Pharmaceuticals LLC | $13.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.